Warsame M, Perlmann H, Ali S, Hagi H, Farah S, Lebbad M, Björkman A
Department of Infectious Disease, Karolinska Institute, Roslagstull Hospital, Stockholm, Sweden.
Trop Med Parasitol. 1989 Dec;40(4):412-4.
Pf155 (RESA), a malaria antigen in the membrane of infected red cells, was recently identified as a possible future malaria vaccine candidate. In this study the seroreactivities against this antigen were compared with those against crude parasitic antigens in 195 subjects from a Somali village with mesoendemic malaria. The seroreactivities were determined with immunofluorescence. With age, there was an increased seroreactivity to both Pf155 and the crude parasitic antigens. However, the acquisition of seroreactivity was much slower against Pf155. Hence in the age group 15-24 years, only half of the subjects had detectable antibodies against Pf155.
Pf155（疟原虫红细胞表面抗原）是受感染红细胞膜上的一种疟疾抗原，最近被确定为未来可能的疟疾疫苗候选物。在本研究中，比较了来自索马里一个疟疾中度流行村庄的195名受试者针对该抗原与针对粗制寄生虫抗原的血清反应性。血清反应性通过免疫荧光测定。随着年龄增长，针对Pf155和粗制寄生虫抗原的血清反应性均增加。然而，针对Pf155的血清反应性获得要慢得多。因此，在15至24岁年龄组中，只有一半的受试者具有可检测到的针对Pf155的抗体。
